KCHO-1治疗阿尔茨海默病的II期临床试验方案
BACKGROUND: Alzheimer's disease (AD) is the most common degenerative brain disorder leading to dementia, characterized by a slow onset and gradual progression.…
要点
- KCHO-1是一种具有抗炎和神经保护特性的草药提取物
- 试验采用三臂设计,比较两种剂量与安慰剂
- 主要结局为ADAS-K-cog,次要结局包括多项认知与功能量表
核心结论
- 本试验旨在确定KCHO-1治疗阿尔茨海默病的最佳剂量,并验证其安全性和有效性。
关键数值与推荐
- 干预措施为KCHO-1 1.6 g、2.4 g或安慰剂。
- 主要结局为ADAS-K-cog。
- 次要结局包括K-MMSE、K-IADL、NPI-Q、CDR、GDS、KQOL-AD、R-MBPC和S-GDpS。
- 记录严重不良事件和总体不良事件的发生频率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alzheimer's disease (AD) is the most common degenerative brain disorder leading to dementia, characterized by a slow onset and gradual progression. Early symptoms typically include difficulties in recalling recent events, which later extend to impairments in various cognitive functions such as language, judgment, and problem-solving, ultimately resulting in the complete loss of independent daily functioning. KCHO-1, a herbal extract with demonstrated anti-inflammatory and neuroprotective properties, has shown promise in mitigating the effects of neurodegenerative disorders. This study aims to develop a protocol for determining the optimal dosage of KCHO-1 in treating AD, providing a foundation for its potential therapeutic application. METHODS: This is a phase II, multi-center, 3-arm randomized controlled study. Sixty patients with AD will be randomly assigned to one of three groups. Each group will receive a standard treatment with 1.6 g of KCHO-1, 2.4 g of KCHO-1, or a placebo. The primary outcome is ADAS-K-cog. Secondary outcomes include results of K-MMSE, K-IADL, NPI-Q, CDR, GDS, KQOL-AD, R-MBPC, and S-GDpS. The frequencies of severe adverse events as well as overall adverse occurrences are listed and documented. The trial protocol has been approved by the Institutional Review Board of the Wonkwang University Hospital Gwangju Korean Medical Center and Wonkwang University Hospital (WKIRB 2021/14-19 and WKUH IRB 2023-10-005-012, respectively). The Ministry of Food and Drug Safety (MFDS) approved the drug as an investigational new drug (30731). DISCUSSION: The purpose of this study is to establish the ideal KCHO-1 dosage. Additionally, it seeks to validate KCHO-1's safety and effectiveness in reducing functional deterioration in AD patients. TRIAL REGISTRATION: Korean National Clinical Trial Registry CRIS; KCT0008433. Registered on 12 May 2023.
引用
- Shin J, Jeong TS, Jung HS, et al. Phase II clinical trial of KCHO-1 for Alzheimer's disease: study protocol for a multicenter, randomized, double-blind, multi-dose, placebo trial. Trials. 2026. PMID: 41749280. doi:10.1186/s13063-026-09572-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。